Dr. Chapa’s OBGYN Clinical Pearls

Dr. Chapa’s OBGYN Clinical Pearls

By Dr. Chapa’s Clinical PearlsScience
Download on the App Store
  • Favorites

    92

    Followers

  • Typical duration

    19 min

    per episode

Based on Podcast App listening data

Dr. Chapa’s OBGYN Clinical Pearls episodes

  • Avocados Prevent Cesarean? Not So Fast.

    If you’ve scrolled through your feed lately, you might havecaught a buzzworthy new study suggesting that eating avocados during pregnancy could lower your odds of having a C-section by more than a quarter. On the surface, it sounds like an easy, delicious prescription—grab some guacamole and avoid major surgery. Today, we’re going to put that study under the microscope. We’re dissecting the November 2026 Kuopio Birth Cohort paper by Cheng and colleagues to see what the data actually says- and more importantly, what itdoesn't. Because in obstetrics and nutritional science, how a study is designed, who funds it, and what variables get left out can completely change how we interpret the results. Understanding a study's limitations isn't about being cynical; it's about separating real clinical breakthroughs from statistical noise so you can make truly informed decisions. Let's dive into the data- no spin.

     

    🛒 Aspire Drinks - Greentea-powered energy drink:

    💰 Get 20% OFF | PromoCode: CHAPANOSPINOBG

    https://promocode.to/aspire-drinks/chapanospinobg-2yc

    1.     F. W. Cheng, N. A. Ford, K. Backman, et al., “Maternal Avocado Consumption and Pregnancy and Newborn Outcomes: ProspectiveKuopio Birth Cohort,” Journal of Obstetrics and Gynaecology Research 52, no. 11(2026): e70561, https://doi.org/10.1111/jog.70561 

    2.     Nature.com: https://www.nature.com/articles/s41390-025-03968-4

     

    18 min
  • Beware “The Dolphin Sign” at Second Stage

    Welcome back to the show. Let’s take a quick step back in time. Think about how far we’ve come: we went from pressing a classic OB fetoscope up against a pregnant belly just to catch a faint, muffled thumping, to relying on advanced, continuous electronic monitoring. We live in an era of high-tech obstetrics. But even with all these modern advancements, room for error still exists, especially during the high-stakes chaos of the second stage of labor. In fact, this exact vulnerability was flagged as a critical warning in ACOG’s Clinical Practice Guideline Number 10. The issue? Relying on an external fetal heart rate Doppler that can silently mistake the maternal heart rate for the fetal heart rate. And now, a team of authors from New York writing in the AJOG are bringing even sharper focus to this danger, introducing a brand-new term for your clinical radar: "The Dolphin Sign." It’s a striking visual descriptor for a phenomenon born from maternal-fetal Doppler ambiguity—and if it goes unrecognized, it can leave a child at a devastating risk of acidosis. If you want to know how to spot it, what it means for your delivery room management, and how to protect your patients, you're going to want to stay tuned.

    PROMO CODE: https://aspiredrinks.com/discount/CHAPANOSPINOBG

    1. ACOG CPG #10, October 2025

    2. VINTZILEOS A, CHAVEZ M. The Dolphin Sign on fetal heart rate tracing: maternal-fetal signal ambiguity during the second stage of labor. American Journal of Obstetrics & Gynecology, 2026; 0

    3. Kiely, D.J., Oppenheimer, L.W. & Dornan, J.C. Unrecognized maternal heart rate artefact in cases of perinatal mortality reported to the United States Food and Drug Administration from 2009 to 2019: a critical patient safety issue. BMC Pregnancy Childbirth 19, 501 (2019). https://doi.org/10.1186/s12884-019-2660-5


    20 min
  • Severe BP Intrapartum, Non-severe on Repeat: PreE with Severe Nuances

    Now, if you’ve been in OB care for more than a month, you know that preeclampsia is one of those topics we talk about constantly. We have endless guidelines, algorithms, and diagnostic criteria plastered all over our unit walls. But here’s the truth: despite all the literature out there, the real world doesn't always read the textbook. The clinical nuances… The gray areas…That’s where things get tricky. Take a classic labor and delivery scenario: Your patient in active labor throws a blood pressure in the severe range. You follow protocol and get a repeat BP 15 minutes later—and it’s back down in the non-severe range. So, what now? Does that initial single severe reading still count toward a diagnosis of preeclampsia with severe features, or does severe range have to be sustained? And let’s make it even more interesting: What if later in the shift, she hits another severe-range BP, but again, it drops to non-severe on the 15-minute recheck- yet both of those spikes under that standard 4-hour window? Is that officially preeclampsia with severe features? That right there is the absolute peak of clinical nuance. It’s the difference between blindly following a chart and actually delivering sharp, nuanced bedside care. So, grab your coffee, settle in, and let's break down the details.


    ASPIREDRINKS.com PROMO CODE: https://aspiredrinks.com/discount/CHAPANOSPINOBG


    1. ​ ACOG PB 222
    2. ​ Countouris ME, Bello NA. Advances in Our Understanding of Cardiovascular Diseases After Preeclampsia. Circ Res. 2025 Mar 14;136(6):583-593. doi: 10.1161/CIRCRESAHA.124.325581. Epub 2025 Mar 13. PMID: 40080539; PMCID: PMC11921930.


    25 min
  • Latest HPV Cervical Guidelines: ACOG and HPV 56/59/66

    Yes, we have covered cervical cancer screening many, many times on this show. It is truly a testament to science and research just how far we have come from using slide-based cytology for cervical cancer screening. Primary high-risk HPV, as a screening modality, has been favored for many years and is now officially part of the age-based, ACOG cervical cancer screening guideline (July 2026). We will summarize that update in this episode. Plus, we will also review about what to do when the hrHPV expanded genotype panel returns positive for 56/59/66. Modern cervical screening reports frequently refer to HPV 56, 59, and 66, typically grouping them together into a single pooled result (often labeled as a trio "HPV 56/59/66"). This is due to the widespread adoption of extended HPV genotyping technology. WE, what do we do with that? Listen in for details.

    1. ACOG Committee Statement No. 28: Screening for Cervical Cancer; July 2026

    2. Massad LS, Clarke MA, Perkins RB, Garcia F, Chelmow D, Cheung LC, Darragh TM, Egemen D, Lorey TS, Nayar R, Newman M, Risley C, Smith RA, Wentzensen N; Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee. Applying Results of Extended Genotyping to Management of Positive Cervicovaginal Human Papillomavirus Test Results: Enduring Guidelines. J Low Genit Tract Dis. 2025 Apr 1;29(2):134-143. PMC11939109.


    19 min
  • ACOG POI Update (Oct 2026)

    If you work in women’s health, you already know the golden rule: just when you think you’ve got a guideline memorized, the ink dries, and the updates drop. Medicine moves fast, and this month is no exception. Today, we are diving straight into the fresh-off-the-press October 2026 ACOG Practice Advisory on Premature Ovarian Insufficiency. Now, if you’re thinking, 'Wait, didn’t ACOG just reaffirm their POI guidance last year in 2025?'- you aren't crazy! They did. But clinical evidence doesn't wait around. ACOG has officially updated its stance to align directly with international consensus from ESHRE-the European Society of Human Reproduction and Embryology. So, what actually changed? How are we shifting our diagnostic thresholds, workups, and long-term hormone replacement strategies for these patients? We're covering all of it-the new shifts, the clinical pearls, and what you need to change in your practice starting today. Let’s get into it.

    1. ACOG PA POI October 2026

    2. ACOG Committee Opinion No. 605, Primary Ovarian Insufficiency in Adolescents and Young Women; July 2014.


    20 min
  • Myfembree as BC? ASRM Data

    Back in 2021, we discussed the FDA approval of a combination GNRH antagonist (relagolix) with estradiol and norethindrone. This was originally approved to treat uterine fibroid related heavy menstrual bleeding. It is also now approved for endometriosis care. In theory, this should also be an effective contraceptive agent. However, the FDA label strictly cautions against its use for birth control. In this episode, we will discuss data from the recent ASRM 2026 annual conference that looked at this medication's ability to possibly function as hormonal contraception. But there is a catch. Listen in for details.

    1. https://www.medscape.com/viewarticle/fibroid-drug-relugolix-may-act-contraceptive-2026a10015db

    2. Myfembreehcp.com



    19 min
  • Maternal Fragile X Carrier: NEXT STEPS

    Today, we’re diving into a topic that has completely transformed prenatal care over the past decade—non-invasive prenatal testing, or NIPT. Thanks to recent technological leaps, cfDNA, cell-free fetal DNA, is giving us unprecedented visibility through just a simple maternal blood draw. Take Fetal Focus by Natera, for example, or the UNITY Reflex Screen from BillionToOne. These options offer single-gene NIPT that can evaluate fetal risk for specific autosomal recessive conditions, like cystic fibrosis, spinal muscular atrophy, or sickle cell disease, to better risk stratify the fetus without going immediately to an invasive diagnostic test. Similarly, The UNITY CONFIRM option also evaluates whether a fetus is at low or high risk for fetal aneuploidies—chromosomal conditions like Trisomy 21, 18, and 13 up to a set gestational age as an alternative to amniocentesis, although that is still considered a screening test. That specialized test uses intact circulating fetal cells to non-invasively help assess aneuploidy risk without an immediate invasive procedure. But what happens when the maternal carrier screen comes back positive for a complex genetic variant, specifically a Fragile X mutation (an FMR1 gene expansion)? Should that automatically trigger a referral for diagnostic testing? In this episode, we’re going to cover exactly how Fragile X inheritance works, why current non-invasive technologies hit a wall with repeat expansion disorders, and what clinical decision steps patients and providers need to take next.

    1. Carrier Screening for Genetic Conditions; ACOG CO NUMBER 691. MARCH 2017

    (REAFFIRMED 2025)

    2. https://utswmed.org/medblog/fragile-x-syndrome-pregnancy/



    21 min
  • Choline in Pregnancy: New Oct 2026 RCT

    Choline is not a nutrient that the human body can synthesize in sufficient quantities; it must be obtained from dietary sources (eggs, meat, fish, dairy products, grains, and nuts). Its a water-soluble amine that serves as a precursor for phospholipids, which are vital components of cell membranes. Plus, it’s a vital component of acetylcholine, a neurotransmitter involved in numerous brain functions. Inadequate choline intake during fetal organogenesis is associated with neural tube defects and cognitive deficits in offspring. In the mother, low choline use has been associated with preeclampsia, preterm birth and possible fetal growth restriction. While choline is crucial for fetal development and maternal outcomes, studies suggest that many pregnant women don’t meet the recommended dietary intake, potentially risking maternal and fetal health. ACOG recommends that pregnant women consume 450 mg of choline each day, although there is no universal internationally agreed upon dose for proper maternal supplementation. Of note, the current recommendations for pregnant women were set in 1998 and were based on the amount of choline needed to prevent liver dysfunction in men, not on the more relevant outcome of offspring neurocognitive development. In this episode, we will highlight a new RCT (Article in Press-AJOG; Oct 19, 2026) on Choline supplementation in pregnancy and early childhood behavioral and cognitive outcomes. While the results were promising, there are some limitations to this study. Listen in for details.

    1. Jaiswal A, Dewani D, Reddy LS, Patel A. Choline Supplementation in Pregnancy: Current Evidence and Implications. Cureus. 2023 Nov 8;15(11):e48538. doi: 10.7759/cureus.48538. PMID: 38074049; PMCID: PMC10709661.

    2. Hunter S, Hoffman M, Law A .Prenatal Maternal Phosphatidylcholine and Children’s Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial. American Journal of Obstetrics & Gynecology, 2026;

    3. Bahnfleth CL, Strupp BJ, Caudill MA, Canfield RL. Prenatal choline supplementation improves child sustained attention: A 7-year follow-up of a randomized controlled feeding trial. FASEB J. 2022 Jan;36(1):e22054.

    4. Cai F, Young BK, Mccoy JA. Commercially Available Prenatal Vitamins Do Not Meet American College of Obstetricians and Gynecologists Nutritional Guidelines. Am J Perinatol. 2024 May;41(S 01):e2547-e2554.


    20 min
  • A DCC Conundrum

    Delayed cord clamp is standard of care. On today’s episode, we are stepping into a high-pressure dilemma in the labor and delivery room. Imagine this (which doesn’t need a lot of imagination, because it is a real event which occurred to one of our podcast family members): A mother has carefully drafted a birth plan. One of her non-negotiable requests is delayed cord clamping for two full minutes. But the moment the baby is delivered, it becomes clear that the infant is non-vigorous: floppy, pale, and not breathing. The baby urgently needs immediate resuscitation.

    The physician reaches for the cord shears, but the mother demands: "No! Wait the two minutes! It's my decision!" What happens next? Whose rights win out? Today, we’re exploring clinical guidelines, the core ethical principles, the legal mandates, and state FOUR established norms that govern the delivering professional’s actions.


    1. American College of Obstetricians and Gynecologists Committee on Clinical Consensus–Obstetrics. ACOG Clinical Practice Update: An Update to Clinical Guidance for Delayed Umbilical Cord Clamping After Birth in Preterm Neonates. Obstet Gynecol. 2025 Jul 24;146(3):442-444. doi: 10.1097/AOG.0000000000006020. PMID: 40706055.

    2. Jabeen S, Salam SS, Gillespie S, Hasan M, Islam S, Chowdhury AT, Ameen S, Balen J, Rahman AE, Arifeen SE, Nahar Q, Anumba DO. Delayed cord clamping: Perceptions, practices and influencers among the healthcare providers of selected healthcare facilities in Bangladesh. PLoS One. 2024 Dec 5;19(12):e0313938.


    18 min
  • ASH New Ferritin Recs for Women (Sept 2026)

    Here is a sobering fact: Iron deficiency is one of the most common health conditions in the world. Iron deficiency affects an estimated one in three people, yet many go undiagnosed and untreated despite widespread treatment options. Iron deficiency can progress to iron deficiency anemia. If you’ve been listening for a while, you know we have banged the drum on this podcast time and time again about why serum ferritin matters. We’ve talked about how so many people suffer from low iron stores even when their basic blood work comes back looking "normal," and why we have to look way beyond just standard iron deficiency anemia. Well, guess what? The medical establishment is officially catching up! In September 2026, the American Society of Hematology (ASH) released brand new, evidence-based recommendations that are set to completely change how we diagnose iron deficiency. Published in ASH’s prestigious, peer-reviewed journal Blood Advances, these new guidelines were brought together by a multidisciplinary team of experts across multiple medical specialties to redefine critical thresholds- especially for women and during pregnancy. Today, we are diving deep into what these new guidelines actually mean for us. Listen in for details

    1. https://www.hematology.org/newsroom/press-releases/2026/ash-sets-new-standards-for-diagnosing-iron-deficiency

    2. https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025015950/570502/American-Society-of-Hematology-2026-guidelines-for



    21 min

About Dr. Chapa’s OBGYN Clinical Pearls

From the publisher's feed

Relevant, evidence based, and practical information for medical students, residents, and practicing healthcare providers regarding all things women’s healthcare! This podcast is intended to be…

Best of Dr. Chapa’s OBGYN Clinical Pearls

Ranked by our users in the last 21 days

More shows like Dr. Chapa’s OBGYN Clinical Pearls

The Green Room: A Podcast from Obstetrics & Gynecology by Obstetrics & Gynecology (Green Journal)

The Green Room: A Podcast from Obstetrics & Gynecology

65 Listeners

White Coat Investor Podcast by Dr. Jim Dahle of the White Coat Investor

White Coat Investor Podcast

2,445 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,425 Listeners

Evidence Based Birth® by Rebecca Dekker, PhD, RN

Evidence Based Birth®

1,036 Listeners

Health By Heather Hirsch by Heather Hirsch MD

Health By Heather Hirsch

224 Listeners

CREOGs Over Coffee by CREOGs Over Coffee

CREOGs Over Coffee

559 Listeners

As a Woman by Natalie Crawford, MD

As a Woman

1,106 Listeners

You Are Not Broken by Kelly Casperson, MD

You Are Not Broken

1,267 Listeners

Fertility Docs Uncensored by Various

Fertility Docs Uncensored

286 Listeners

The Critical Care Obstetrics Podcast by Clinical Concepts in Obstetrics

The Critical Care Obstetrics Podcast

228 Listeners

All the Hacks: Money, Points & Life by Chris Hutchins

All the Hacks: Money, Points & Life

1,606 Listeners

Dr. Streicher’s Inside Information: Menopause, Midlife, and More by Lauren Streicher, MD

Dr. Streicher’s Inside Information: Menopause, Midlife, and More

357 Listeners

OvaryActive by Dr Rebecca Dunsmoor-Su, Dr Amy Voedisch

OvaryActive

86 Listeners

Dr. Chapa's OBGYN No Spin Podcast by Hector Chapa

Dr. Chapa's OBGYN No Spin Podcast

22 Listeners

unPAUSED with Dr. Mary Claire Haver by Audacy | Mary Claire Haver, MD

unPAUSED with Dr. Mary Claire Haver

1,190 Listeners